Replies to post #27981 on BioCurex, Inc.(fka BOCX)

[Gold Seeker]

Opportunity, BioCurex is in a bad financial position.

He only has money to last until the end of the year. He cannot afford to run any expensive clinical trials in order to submit a 510k.

Just 15 days ago, Moro submitted a 10Q that stated the licensees would obtain FDA approval.

"Our business model is to develop internally our RECAF cancer diagnostic
platform to the stage where individual applications can be partnered or licensed
in strategic relationships for regulatory approval "

If you notice, the PR says nothing about planning to run clinical trials.

" to help expedite the FDA approval of its RECAF(TM) cancer marker test and to compile the large amount of data acquired by BioCurex for publication in peer-reviewed medical journals"

It does say help compile past data for medical journals but that has nothing to do with FDA approval.

Opportunity, this is just hype. Journal articles wont do anything for the company. They have had many of those. He has no money for the necessary clinical trials and it clearly contrary to what was stated 15 days ago. Also, this is not a new agreement just signed. It was signed on Jan 3, 2011.

Moro even bought back stock in an attempt to support the share price. This PR is no different.

Sorry Opportunity, but that is just how I see it.

[Gold Seeker]

Opportunity, at one time not long ago, you mentioned how great Radient Pharmaceuticals was doing.

Well, they got caught in a scam on sales in India. There was no government program for Onko Sure as they claimed and sales have been nil.

Doesn't that sort of remind you of BioCurex China where samples had been collected awaiting testing with RECAF?

The difference was that Radient got caught. Their stock is now at 15 cents with money for two months or so and $10 million in defaulted loans with creditors demanding payment. Revenue last quarter as $31,000 and bankruptcy is likely.

Do you also remember when "new management" here was heralded as a turnaround? No new management just as I stated.

I also said the Paulson investors would take this stock to zero. Well, it appears to be well on its way.